卡马西平联合盐酸洛美利嗪胶囊治疗偏头痛的临床疗效

Clinical Efficacy of Lomerizine Hydrochloride Capsules Combined with Carbamazepine in the Treatment of Migraine

目的探讨卡马西平联合盐酸洛美利嗪胶囊治疗偏头痛患者的临床疗效。方法选取辽宁大学医院2015年3月至2018年3月收治的80例偏头痛患者作为研究对象,根据治疗方法不同分为观察组(46例)与对照组(34例)。对照组患者给予盐酸洛美利嗪胶囊,观察组患者在对照组基础上联合卡马西平治疗。比较两组患者治疗前后头痛发作频率、24 h内头痛缓解维持时间、视觉模拟评分法(VAS),并观察其不良反应发生情况。结果治疗前,两组患者头痛发作频率和24 h内头痛缓解维持时间比较差异均无统计学意义(均P>0.05);治疗后,观察组患者的头痛发作频率明显降低,24 h内头痛缓解维持时间显著延长,两组患者的两项指标比较,差异均有统计学意义(均P<0.05)。治疗前,观察组与对照组患者的VAS评分分别为(7.57±1.03)分、(7.46±1.17)分,组间比较差异无统计学意义(P>0.05);治疗后,观察组患者的VAS评分为(2.07±0.86)分,明显低于对照组的(3.82±0.90)分,差异有统计学意义(P<0.05)。观察组患者不良反应发生率为13.04%,与对照组的11.76%比较,差异无统计学意义(P>0.05)。结论使用卡马西平联合盐酸洛美利嗪胶囊治疗偏头痛,能明显降低患者的头痛发作频率,延长24 h内头痛缓解维持时间,减轻患者疼痛程度,且联合用药并未明显增加不良反应发生,安全性较高。

Objective To explore the clinical efficacy of carbamazepine combined with lomalazine hydrochloride capsules in the treatment of migraine. Methods According to different treatment methods, the 80 migrine patients selected from Liaoning University Hospital from March 2015 to March 2018 were divided into observation group(46 cases) and control group(34 cases). Patients in the control group were given lomethazine hydrochloride capsules orally, while the observation group was combined with carbamazepine oral administration on the basis of the control group. Both groups were treated for 90 days. The frequency of headache onset before and after treatment, duration of headache remission within 24 hours, and visual analogue scale(VAS) score before and after treatment were compared between the two groups. Adverse reactions were observed in the two groups. Results Before treatment, the frequency of headache attack and the duration of headache remission within 24 hours in the two groups were not statistically significant(P>0.05). After treatment, the frequency of headache attack was significantly reduced in the observation group, and the duration of headache relief was significantly prolonged within 24 hours. Compared the two indexes of the two groups were, the difference was statistically significant(P<0.05). Before treatment, VAS scores of the observation group and the control group were respectively(7.57±1.03) and(7.46±1.17), There was no significant difference between the groups(P>0.05). After treatment, VAS score of both groups decreased significantly. Patients in the observation group(2.07±0.86), the score was significantly lower than that of the control group(3.82±0.90). The difference between the two groups was statistically significant(P<0.05). The incidence of adverse reactions in the observation group was 13.04%, and the difference between the two groups was not statistically significant compared with 11.76% of the control group(P>0.05). Conclusion The application of carbamazepine combined with lomerizine hydrochloride capsules for the treatment of migraine can significantly reduce the frequency of headache attack, extend the duration of headache relief for 24 hours, and reduce the pain degree of patients. There was no significant increase in adverse reactions, which means the higher safety.